Patents by Inventor Jonathan Bortz

Jonathan Bortz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190125828
    Abstract: The present disclosure provides a single dose form composition to optimize the relationship between the ‘Folate-Cobalamin’ and ‘Choline-Betaine’ pathways. Single dose form compositions disclosed herein ensure an adequate intake of the rate limiting compounds that have been demonstrated to reduce the efficiency of this vital metabolic axis, and methods of use thereof.
    Type: Application
    Filed: March 20, 2017
    Publication date: May 2, 2019
    Inventor: Jonathan Bortz
  • Publication number: 20170281554
    Abstract: A preparation for releasing an active substance, such as iron, in the upper intestine includes an oral dosage form having an external coating, a coating matrix enveloping the oral dosage form, and the active substance embedded in the coating matrix. The active substance disintegrates from the coating matrix within at least one of the stomach, duodenum, upper jejunum, or any combination thereof.
    Type: Application
    Filed: March 29, 2017
    Publication date: October 5, 2017
    Inventor: Jonathan Bortz
  • Publication number: 20130172279
    Abstract: A pharmaceutical composition comprises (a) an antibacterial agent in an antibacterially effective amount, illustratively comprising clindamycin or a pharmaceutically acceptable salt or ester thereof; and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection.
    Type: Application
    Filed: July 25, 2012
    Publication date: July 4, 2013
    Applicant: DRUGTECH CORPORATION
    Inventors: Jonathan Bortz, R. Saul Levinson, Mitchell Kirschner, Robert C. Cuca
  • Patent number: 8425956
    Abstract: Mixed amino acid/mineral compounds can include at least two amino acids bound to a central mineral atom. The combination of amino acids can be tailored to provide improved solubility, absorption, and/or bioavailability of the mineral. Optionally, organic acids can be bound to the mineral or combined with the chelate in order to further improve solubility, absorption, and/or bioavailability. Compositions including one or more mixed amino acid/mineral compounds can be included in therapeutic regimens for indications in which the mineral may treat and/or prevent a condition or symptom.
    Type: Grant
    Filed: July 25, 2011
    Date of Patent: April 23, 2013
    Assignee: Albion International, Inc.
    Inventors: R. Charles Thompson, Clayton Ericson, Stephen Ashmead, Jonathan Bortz
  • Publication number: 20120022162
    Abstract: Mixed amino acid/mineral compounds can include at least two amino acids bound to a central mineral atom. The combination of amino acids can be tailored to provide improved solubility, absorption, and/or bioavailability of the mineral. Optionally, organic acids can be bound to the mineral or combined with the chelate in order to further improve solubility, absorption, and/or bioavailability. Compositions including one or more mixed amino acid/mineral compounds can be included in therapeutic regimens for indications in which the mineral may treat and/or prevent a condition or symptom.
    Type: Application
    Filed: July 25, 2011
    Publication date: January 26, 2012
    Applicant: Albion International Inc.
    Inventors: R. Charles Thompson, Clayton Ericson, Stephen Ashmead, Jonathan Bortz
  • Publication number: 20110251141
    Abstract: A pharmaceutical composition comprises (a) an antibacterial agent in an antibacterially effective amount, illustratively comprising clindamycin or a pharmaceutically acceptable salt or ester thereof; and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection.
    Type: Application
    Filed: June 20, 2011
    Publication date: October 13, 2011
    Applicant: DRUGTECH CORPORATION
    Inventors: Jonathan Bortz, R. Saul Levinson, Mitchell Kirschner, Robert C. Cuca
  • Patent number: 8007846
    Abstract: Mixed amino acid/mineral compounds can include at least two amino acids bound to a central mineral atom. The combination of amino acids can be tailored to provide improved solubility, absorption, and/or bioavailability of the mineral. Optionally, organic acids can be bound to the mineral or combined with the chelate in order to further improve solubility, absorption, and/or bioavailability. Compositions including one or more mixed amino acid/mineral compounds can be included in therapeutic regimens for indications in which the mineral may treat and/or prevent a condition or symptom.
    Type: Grant
    Filed: January 16, 2007
    Date of Patent: August 30, 2011
    Assignee: Albion International, Inc.
    Inventors: R. Charles Thompson, Clayton Ericson, Stephen Ashmead, Jonathan Bortz
  • Publication number: 20080139655
    Abstract: A pharmaceutical composition comprising levodopa is provided that, when administered in a unit dosage amount of levodopa of about 100 to about 500 mg at a dosage interval of about 6 to about 24 hours, exhibits a sufficiently long release period and a sufficiently long residence time in the upper gastrointestinal tract to provide a trough concentration of levodopa in plasma of the subject that is not lower than a minimum threshold concentration below which adverse motor effects are observed in the subject. A method for treating Parkinson's disease in a subject is also provided, comprising orally administering such a composition to the subject in a unit dosage amount of levodopa of about 50 to about 1000 mg at a dosage interval of about 3 to about 24 hours.
    Type: Application
    Filed: September 5, 2007
    Publication date: June 12, 2008
    Applicant: DrugTech Corporation
    Inventors: Jonathan Bortz, Michael Grimshaw, David F. Erkoboni, Michael F. Dickus
  • Publication number: 20080085877
    Abstract: A method for preventing or treating a catamenial migrainous disorder in a female subject comprises administering to a vulvovaginal surface of the subject a pharmaceutical composition that is bioadhesive thereto and comprises at least one estrogenic compound in an amount of about 50 ?g to about 1000 ?g estradiol equivalent per unit dose of the composition. A related method comprises administering to a vulvovaginal surface of the subject a pharmaceutical composition comprising at least one estrogenic compound, wherein upon administration of the composition to the vulvovaginal surface, a decline in serum estradiol concentration during a luteal phase of a menstrual cycle is moderated.
    Type: Application
    Filed: August 10, 2006
    Publication date: April 10, 2008
    Applicant: DrugTech Corporation
    Inventor: Jonathan Bortz
  • Publication number: 20080003262
    Abstract: A method for treating non-infectious inflammatory vulvovaginitis comprises administering to a vulvovaginal surface a pharmaceutical composition that comprises clindamycin in an amount of about 125 mg to about 400 mg per unit dose of the composition; wherein the composition is bioadhesive to the vulvovaginal surface, and upon application of the composition to the vulvovaginal surface the clindamycin is released over a period of about 3 hours to about 14 days. A related method comprises administering to a vulvovaginal surface a pharmaceutical composition comprising clindamycin or a pharmaceutically acceptable salt or ester thereof, wherein the composition has at least one non-lipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. A pharmaceutical composition comprises (a) clindamycin or a pharmaceutically acceptable salt or ester thereof in a clindamycin equivalent amount of about 2.
    Type: Application
    Filed: June 28, 2007
    Publication date: January 3, 2008
    Applicant: DrugTech Corporation
    Inventors: R. Saul Levinson, Robert C. Cuca, Jonathan Bortz
  • Publication number: 20070224226
    Abstract: A pharmaceutical composition comprises (a) metronidazole in an antibacterially effective amount; and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection.
    Type: Application
    Filed: December 28, 2006
    Publication date: September 27, 2007
    Applicant: DrugTech Corporation
    Inventors: R. Levinson, Jonathan Bortz, Mitchell Kirschner, Robert Cuca
  • Publication number: 20070172551
    Abstract: Mixed amino acid/mineral compounds can include at least two amino acids bound to a central mineral atom. The combination of amino acids can be tailored to provide improved solubility, absorption, and/or bioavailability of the mineral. Optionally, organic acids can be bound to the mineral or combined with the chelate in order to further improve solubility, absorption, and/or bioavailability. Compositions including one or more mixed amino acid/mineral compounds can be included in therapeutic regimens for indications in which the mineral may treat and/or prevent a condition or symptom.
    Type: Application
    Filed: January 16, 2007
    Publication date: July 26, 2007
    Applicant: ALBION ADVANCED NUTRITION
    Inventors: R. Thompson, Clayton Ericson, Stephen Ashmead, Jonathan Bortz
  • Publication number: 20070154516
    Abstract: A pharmaceutical composition comprises a first active (e.g., antibacterial) agent and a second (e.g., antifungal) active agent, and comprises a component that is adapted for bioadhesion to a vulvovaginal surface. The composition provides differential release of the active agents at such a surface, wherein the second active agent exhibits a release profile that is substantially delayed, extended and/or inverted relative to the release profile of the first active agent.
    Type: Application
    Filed: December 28, 2006
    Publication date: July 5, 2007
    Applicant: DrugTech Corporation
    Inventors: Jonathan Bortz, R. Levinson
  • Publication number: 20070154498
    Abstract: A method for preventing stenosis and thrombosis of an AV graft is disclosed. An essential fatty acid emulsion is administered to the patient through the AV graft, preferably during dialysis, whereby the anti-inflammatory properties of the essential fatty acid emulsion prevent complications typical of AV grafts.
    Type: Application
    Filed: December 6, 2006
    Publication date: July 5, 2007
    Inventors: Jonathan Bortz, R. Levinson
  • Publication number: 20070110805
    Abstract: This invention is directed generally to modified-release pharmaceutical compositions, and, more particularly, to modified-release anesthetic- or analgesic-comprising pharmaceutical compositions that are bioadherent to a vaginal cavity surface, vulva surface, or skin. This invention also is directed generally to methods for preparing such compositions, methods of treatment using such compositions, uses of such compositions to prepare medicaments, and kits comprising such compositions.
    Type: Application
    Filed: May 8, 2006
    Publication date: May 17, 2007
    Inventors: R. Levinson, Jonathan Bortz, Elio Mariani, Daniel Thompson
  • Publication number: 20070036848
    Abstract: A pharmaceutical composition comprises at least one estrogenic compound, the composition being adapted for application in a unit dose amount to a vulvovaginal surface and having at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface, wherein the at least one estrogenic compound is present in an amount of about 5 to about 1000 ?g estradiol equivalent per unit dose of the composition, and upon application of the composition to the vulvovaginal surface the at least one estrogenic compound is released over a period of about 3 hours to about 30 days. The composition is useful for vulvovaginal administration to treat atrophic vaginitis or a disorder associated therewith, for example in a menopausal or postmenopausal woman.
    Type: Application
    Filed: August 10, 2006
    Publication date: February 15, 2007
    Applicant: DrugTech Corporation
    Inventors: Jonathan Bortz, Thomas Riley
  • Publication number: 20060140990
    Abstract: A pharmaceutical composition comprises (a) an antibacterial agent in an antibacterially effective amount, illustratively comprising clindamycin or a pharmaceutically acceptable salt or ester thereof, and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection.
    Type: Application
    Filed: January 5, 2006
    Publication date: June 29, 2006
    Applicant: DrugTech Corporation
    Inventors: Jonathan Bortz, R. Levinson, Mitchell Kirschner, Robert Cuca
  • Publication number: 20060134227
    Abstract: Nutritional or dietary supplement compositions that promote and/or maintain dietary iron absorption through administration of iron with an organic acid and optionally similar iron absorption promoters are provided. Also provided are methods of nutritional or dietary supplementation using one or more compositions that promote and/or maintain health through the prevention, stabilization, reversal and/or treatment of disorders associated with iron deficiency.
    Type: Application
    Filed: December 22, 2004
    Publication date: June 22, 2006
    Inventors: Jonathan Bortz, Mitchell Kirschner, David Hermelin
  • Publication number: 20060135610
    Abstract: Compositions that promote and/or maintain cardiovascular health through the treatment of one or more cardiovascular diseases are provided. Also provided are methods for using compositions that promote and/or maintain cardiovascular health through the prevention, stabilization, reversal and/or treatment of coronary artery disease and/or cerebrovascular disease. Such compositions may be used independently to promote and/or maintain cardiovascular health or used in combination with one or more other compositions used in the treatment of various other disease states common to aging and/or a health deteriorating condition.
    Type: Application
    Filed: December 22, 2004
    Publication date: June 22, 2006
    Inventors: Jonathan Bortz, Mitchell Kirschner, Marc Hermelin, David Hermelin